Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia (Q35085867)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia |
scientific article |
Statements
1 reference
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia (English)
1 reference
Meir Wetzler
1 reference
Chris Andrews
1 reference
Laurie A Ford
1 reference
Sheila Tighe
1 reference
Maurice Barcos
1 reference
Sheila N J Sait
1 reference
Annemarie W Block
1 reference
Norma J Nowak
1 reference
Maria R Baer
1 reference
Eunice S Wang
1 reference
Heinz Baumann
1 reference
31 March 2011
1 reference
1 reference
Identifiers
1 reference